The future of medical devices

Invented here, in Aotearoa, New Zealand

Traditional Insulin Pump, Radically low-cost

Fundamentally simple, an insulin pump can be designed using standard off-the-shelf components. We are hoping to launch our traditional insulin pump at up to 20x cost reductions on current commercial devices. The pump will be controlled via your phone using Bluetooth.
Our insulin pump was measured against the appropriate standard (IEC 60601-2-24), showing comparable accuracy to currently available commercial pumps, and a validation clinical trial will begin early 2023, with the goal of regulatory approval by the end of 2024.

Mechanical Insulin Pump, Year Long Battery

Insulin pumps require a reliable power source to generate the energy needed to deliver insulin, usually rechargeable or disposable batteries. These batteries increase cost and size of the pump, usually only lasting up to three weeks before needing charging or replacement.

We have developed a mechanical insulin pump which controls the release of a spring to accurately deliver insulin. Using a spring to deliver insulin enables year long battery life from a single coin cell, reducing cost and greatly simplifying usability.

Non-invasive Blood Glucose Sensor

Our team has been developing a non-invasive glucose monitor which uses infrared light to isolate the spectral fingerprint of glucose in blood. The sensor has the potential to provide non-invasive glucose sensing at far lower costs. We are targeting cost reductions of 10-50x per year compared to current commercial competitors.

Clinical testing at the University of Canterbury and Middlemore/ Auckland Hospital NICUs (N=30+ patients, 200+ measurement pairs versus gold standard glucose measurements) has provided performance consistent with current commercial devices.

Smart Digital Twins for Personalised Care

Our digital twin provides an accurate personalised model of every user, with the ability to adjust insulin delivery to guide care. The digital twin has been validated over 15 years of use in ICUs worldwide, enabling a greater glucose time in range (TIR) compared to standard closed-loop systems.

Widespread rollout of our digital twin would increase equity of access to best care and outcomes, as well as significant economic benefits for individuals, clinicians, and the health system.